YAEL HAYON

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

Protalix BioTherapeutics, Inc.

Filing Date Source Excerpt
2021-09-30 Yael Hayon Consists of 40,553 shares of our common stock issuable upon exercise of outstanding options

Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-04-09